Abstract
Nirmatrelvir-ritonivir (Paxlovid) recently received emergency use authorization for the treatment of coronavirus disease 2019 (COVID-19). Literature has linked numerous cutaneous adverse effects to nirmatrelvir and ritonavir, the copackaged tablets within Paxlovid. A review and comparison of these adverse effects to the common cutaneous manifestations of COVID-19 is provided. Numerous drug-to-drug interactions exist between nirmatrelvir-ritonivir and commonly-used medications within dermatology.
Author supplied keywords
Cite
CITATION STYLE
Albrecht, J. M., Cooper, B. R., Waller, J. D., Presley, C. L., Pulsipher, K. J., Rundle, C. W., & Dellavalle, R. P. (2023, January 1). Nirmatrelvir-ritonivir, COVID-19, and possible adverse cutaneous reactions. Dermatology Online Journal. Dermatology Online Journal. https://doi.org/10.5070/D329160209
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
